Treatment of invasive candidiasis in non-haematological patients
Treatment of invasive candidiasis in non-haematological patients Treatment of invasive candidiasis in non-haematological patients
Question 5: Should the intravascularcatheters be removed < 24h?1 - Yes, when > 24h mortality is higher0%2 - No, but < 48h; > 48h mortality is higher 0%3 - No, but it should be removed0%4 - Removal of the catheter has noeffect on mortality0%
Antifungal agents and survivalCandidemia and invasive candidiasis•7 randomized controlled trials•7 antifungal agents (flu, vori, amB, L-amB, caspo,anidula, mica)•New analysis of all individual patients•Primary endpoint: 30 day survival•Excluding: combination therapy, unknown candidaspecies, multiple species infection•1915 patients!Andes Clin Infect Dis 2012
- Page 5 and 6: EpidemiologyMainly data from the US
- Page 7 and 8: Survival in candidemia, species rel
- Page 9 and 10: Question1 : Which Candida species i
- Page 11 and 12: Incidence and mortality of Candida
- Page 13 and 14: HOW TO IDENTIFY PATIENTSAT RISK FOR
- Page 15 and 16: Question 2: Which factor has the gr
- Page 17 and 18: Identification of patients“Ostros
- Page 19 and 20: Question3: What’s the problem wit
- Page 21 and 22: Identification of patients“Ostros
- Page 23 and 24: Are the risk predictive models gene
- Page 25 and 26: Question 4: Empirical treatment is
- Page 27 and 28: HOW TO PREVENT INVASIVECANDIDIASIS
- Page 29 and 30: Empirical antifungal therapy in ICU
- Page 31 and 32: TREATMENT OF INVASIVECANDIDIASIS
- Page 33 and 34: Why do we choose whichantifungal dr
- Page 35 and 36: Randomized Non-Inferior TrialsAmB v
- Page 37 and 38: Caspofungin vs. Amphotericin B tria
- Page 39 and 40: Micafungin vs. L-AmB in ICU Patient
- Page 41 and 42: Anidulafungin vs. fluconazole study
- Page 43 and 44: Success rates different echinocandi
- Page 45: Question 5: Should the intravascula
- Page 49 and 50: In conclusion• Invasive candidias
- Page 51 and 52: Treatment of candidemia-Candida spe
- Page 53 and 54: Success at EIV treatment by pathoge
- Page 55 and 56: Question 6: Should the intravascula
- Page 57 and 58: Candida Scorein practiceProspective
Antifungal agents and survivalCandidemia and <strong><strong>in</strong>vasive</strong> <strong>candidiasis</strong>•7 randomized controlled trials•7 antifungal agents (flu, vori, amB, L-amB, caspo,anidula, mica)•New analysis <strong>of</strong> all <strong>in</strong>dividual <strong>patients</strong>•Primary endpo<strong>in</strong>t: 30 day survival•Exclud<strong>in</strong>g: comb<strong>in</strong>ation therapy, unknown candidaspecies, multiple species <strong>in</strong>fection•1915 <strong>patients</strong>!Andes Cl<strong>in</strong> Infect Dis 2012
Change language